Combination of transcatheter arterial chemoembiolization and antitumor drugs in the treatment of Hepatocellular carcinoma
10.3760/cma.j.issn.1673-4203.2010.11.016
- VernacularTitle:TACE联合抗肿瘤药物在原发性肝细胞癌治疗中的现状及进展
- Author:
Pan CHEN
;
Xiong DING
;
Shengwei LI
- Publication Type:Journal Article
- Keywords:
Transcatheter arterial chemoembolization;
Vascular endothelial growth factor;
Hepatocellular carcinoma
- From:
International Journal of Surgery
2010;37(11):766-769
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma(HCC)is a common world wide disease.Transcatheter arterial chemoembolization(TACE)has been the first choice for the unresectable midadvanced ones.However, TACE has its own limitation such as high recurrence rate and many complications, what's more, recurrence induced by neovascularization which is stimulated by activation of vascular endothelial growth factors promoted by ischemia and hypoxia in local tissues after the embolization always reduce the effect of treatment.And combination of TACE and anti-angiogenesis therapy is capable to make up the shortage of each other and reduce the recurrence rate, which has been a hot issue for non-surgical treatment of HCC.
